
==== Front
Exp Ther Med
Exp Ther Med
ETM
Experimental and Therapeutic Medicine
1792-0981
1792-1015
D.A. Spandidos

ETM-28-5-12710
10.3892/etm.2024.12710
Articles
Cancer antigen 153: A risk factor for ocular metastases in patients with breast cancer
Ge Qian-Min *
Hu Qiao-Hao *
Liu Jia-Xiang *
Min You-Lan
Liang Rong-Bin
Li Biao
Shi Wen-Qing
Lin Qi
Yuan Qing
Li Qiu-Yu
Shao Yi
Department of Ophthalmology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330006, P.R. China
Correspondence to: Dr Yi Shao, Department of Ophthalmology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, 17 Yongwaizheng Street, Donghu, Nanchang, Jiangxi 330006, P.R. China drsadia@uitm.edu.my freebee99@163.com
*Contributed equally

11 2024
10 9 2024
10 9 2024
28 5 42127 9 2019
19 12 2022
Copyright: © 2024 Ge et al.
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Ocular metastasis (OM) in breast cancer (BC) always predicts poor prognosis. The present study explored differences in tumor markers in patients with BC with and without OM, and attempted to determine risk factors for OM in patients with BC. This study involved 629 patients with BC. Patients' clinical features were tested using χ2 test, unpaired Student's t-test and Mann-Whitney U. These parameters were analyzed using binary logistic regression to obtain risk factors for OM. A receiver operating characteristic curve was then established to determine the diagnostic value for OM. There were no significant differences in age, sex, menopausal state, and pathological type between the two groups. Significantly more axillary lymph node metastases were observed in the OM group compared with the non-ocular metastases group. Cancer antigen 153 (CA153) was revealed to be a significant independent risk factor for OM in patients with BC. The cutoff CA153 value for diagnosis of OM was 43.00 u/ml, the sensitivity was 96.15% and the specificity was 96.02%. In conclusion, CA153 was demonstrated to be a risk factor for OM in patients with BC. High levels of CA153 were associated with OM in patients with BC.

breast cancer
tumor markers
diagnostic value
ocular metastases
Funding: This work was supported by the National Natural Science Foundation of China (grant no. 82160195), Jiangxi Double-Thousand Plan High-Level Talent Project of Science and Technology Innovation (grant no. jxsq2023201036) and the Key R & D Program of Jiangxi Province (grant no. 20223BBH80014).
==== Body
pmcIntroduction

Breast cancer (BC) is the most commonly diagnosed cancer in women globally in addition to being the leading cause of cancer mortality in women in >100 countries, with a continuously increasing incidence (1). Moreover, >1/3 of patients with BC will develop distant metastases such as lung, liver, bone and brain metastases (2-5).

Ocular metastasis (OM), an uncommon distant metastasis, is easily neglected because of its obscure clinical symptoms in the early stage (6). When it develops to an advanced stage, OM causes ocular pain, foreign body sensation, vision loss, visual field defects and other symptoms, thus seriously affecting patients' quality of life (7). Currently, positron emission computed tomography/computed tomography (PET/CT), magnetic resonance imaging (MRI) and ultrasonic testing are often used in clinical practice for diagnosis of OM (8,9). However, these approaches have obvious disadvantages, including their expense and damage from high-dose radiation (10). Thus, it is important to explore improved methods for predicting OM in breast cancer. Serum testing for clinical parameters is a practical method to assess the possibility of distant metastases, as it can shed light on the progress of tumors. Among the various parameters that have been used in clinical practice, tumor markers are considered to be reliable indices to predict distant metastases in patients with cancer (11).

A cancer biomarker is a substance or process that indicates the presence of cancer in the body (12). Measured either in the tumor or in blood, tumor biomarkers can be used to evaluate tumor condition and thus predict the possibility of developing distant metastases (11). Traditional cancer biomarkers include embryonic antigens, as well as protein, carbohydrate, enzyme and hormonal markers (13).

Cancer antigen 153 (CA153) is used to detect Mucin 1 (MUC-1), a transmembrane protein consisting of two subunits (14). MUC-1 is expressed at the apical plasma membrane in normal secretory epithelial cells (15). However, it is released into the serum when metastatic BC occurs (16). Numerous other advanced types of cancer, including ovarian, pancreatic, gastric and lung cancer, also result in elevated CA153 levels (17-20). High levels of C153 can also be observed in a number of benign diseases, including chronic active hepatitis, liver cirrhosis, sarcoidosis and metaplastic anemia (17,21,22). Owing to its low specificity, the use of CA153 in diagnosing early BC has been limited, although it provides useful prognostic information. Numerous studies have demonstrated that high preoperative levels of CA153 are associated with shorter disease-free and overall survival times in patients with BC (23,24).

Other cancer biomarkers have also been used in diagnosing tumors and metastases. In patients with colorectal cancer and liver metastasis, higher carcinoembryonic antigen (CEA) level is associated with shorter median progression-free survival and median liver progression-free survival (25). In Zhao's study (26), the sensitivity and specificity of cancer antigen 125 (CA125) for diagnosing ovarian cancer were 88.2 and 67.4%, respectively. Cancer antigen 199 (CA199) level >300 mg/ml is an independent prognostic factor for postoperative survival in Zheng's study (hazard ratio, 3.76; 95% CI, 2.18-6.49) (27). Alkaline phosphatase (ALP) is used to diagnose bone metastases in BC with a high specificity (93.96%) but a low sensitivity (65.14%) (28).

A number of studies have reported altered levels of CA153 in patients with cancer with metastases at various sites and investigated their diagnostic value. However, whether CA153 levels could be used to detect OM in patients with BC remains unknown. The present retrospective study analyzed levels of CA153 and other common tumor biomarkers of patients with BC to determine their value in diagnosing OM.

Materials and methods

Study design

This study was designed to determine the associations between levels of cancer biomarkers and OM in patients with BC. The data range of sample collection is Jan 2005-Jan 2019. All BC were diagnosed pathologically, and the pathologist was independent from the study. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of the First Affiliated Hospital of Nanchang University (approval no. CDYFY-2015-112; date, 2015-05-06; Nanchang, China). All the methods complied with relevant guidelines and regulations. Breast tissues from patients were resected during surgery and the diagnosis of BC was made on the basis of pathological biopsy. CT and MRI were used to make the OM diagnosis. Inclusion criteria were all patients who were diagnosed with BC based on the pathologically. Exclusion criteria were primary ocular malignant tumor, primary ocular benign tumor and secondary BC. As this is a retrospective study, informed consent of the patients was waived, which was approved by the Ethics Committee at The First Affiliated Hospital of Nanchang University.

Data collection

Age, sex, histopathological subtype and menopausal status were recorded as basic information and analyzed for differences among patients (Table I). As well as CA153, axillary lymph node metastasis (ALNM), CEA, CA125, CA199, ALP and calcium were analyzed as these parameters are frequently used in clinical practice and reflect the condition of tumors in patients with cancer. All clinical indices were collected from medical records when patients were first diagnosed with BC. Consecutive data are represented as mean ± standard deviation.

Statistical analysis

First, basic clinical features including age, sex, histopathological subtype, menopausal status and ALNM number were compared using Fisher's exact test, χ2 test and unpaired Student's t-test. Then, clinical parameters of the ocular metastases (OM) group and non-ocular metastases (NOM) group were compared across different subgroups using the Mann-Whitney U test. Binary logistic regression was carried out to determine independent risk factors for OM. A receiver operating characteristic (ROC) curve was constructed with MedCalc 18.2.1 (MedCalc Software, Ltd.), and the cutoff value, area under the curve (AUC), sensitivity and specificity were obtained. Measurement data are presented as mean ± standard deviation (SD). P<0.05 was considered to indicate a statistically significant difference.

Results

Clinical features of patients with BC

There were 629 patients with BC in total (627 female and two male), of which 26 patients had OM and 603 had NOM. There were no differences in age (P=0.241), sex (P=1.000), menopausal status (P=0.248), or histopathology (P=0.656) between the OM and NOM groups. The average age of patients in the OM group was 45.85±7.76 years, compared with 48.31±10.58 years in the NOM group. In the OM group, 19 patients had premenopausal status and seven were postmenopausal, whereas in the NOM group the numbers were 373 and 230, respectively. Regarding histopathology, the OM group contained 20 cases of invasive ductal carcinoma and six cases of other types. In the NOM group, there were 440 cases of invasive ductal carcinoma and 163 cases of other types. A statistical difference was revealed for ALNM (P<0.001); the OM group contained four cases without ALNM and 22 cases with ALNM, whereas the NOM group contained 259 and 344 cases, respectively. Details are presented in Table I.

Distributions of patients with BC and condition of their distant organ metastases

The top four cities patients came from were Nanchang, Shangrao, Fuzhou, and Jian (marked in red in Fig. 1A). The majority of the patients were from Jiangxi province (marked in red and yellow in Fig. 1A), but there were also 11 patients from other provinces (marked in blue in Fig. 1A). Details of the patient distribution are presented in Fig. 1A.

Numbers of distant organ metastases (bone, liver, lung and brain) in the two groups were counted. Bone was the most common metastatic site for BC, accounting for 25 and 62 cases in the OM and NOM group, respectively (Fig. 1B).

Subgroup analysis and binary logistic regression analysis

To exclude potential confounding by other distant metastases and clarify the diagnostic value of CA153, data were further divided into subgroups. Differences in CA153 levels between the OM group and NOM group were revealed to be statistically significant in each subgroup (Table II). The P-values are summarized in Table III. The binary logistic regression analysis identified CA153 as a risk factor for OM in patients with BC (P<0.001; Table IV).

Sensitivity, specificity, AUC and cutoff value for CA153

A ROC curve for CA153 was established to evaluate its diagnostic value. The AUC for CA153 was 0.977, with a 95% CI of 0.958-0.995. The cutoff value was 43.3 µ/ml, with a corresponding sensitivity of 96.15% and specificity of 96.02% (Fig. 2). Details are presented in Table V.

Discussion

BC has a high incidence of distant metastases and has increased the medical cost burden of our society. Although the widespread use of mammography, PET/CT and MRI has increased the detection rate, there are still some disadvantages (29). Various risk factors and clinical parameters associated with distant metastases of BC have been taken into consideration to make up for the limitations of these techniques (28,30-32) (Table VI).

Tumor marker serum tests are widely used in patients with cancer to evaluate tumor occurrence and condition. Several studies have already investigated the use of tumor markers in a number of types of cancer. Brand et al (33) revealed higher levels of CA199 in patients with pancreatic ductal carcinoma (PDC) compared with healthy controls, indicating that CA199 can be used to diagnose PDC. In Stojkovic's study (34), higher CEA levels are associated with advanced stage in patients with colorectal carcinoma (CRC); the study also demonstrates the use of CEA as a diagnostic factor to predict the severity of CRC. In another study (35), CA125 has been used to diagnose ovarian cancer; the sensitivity and specificity of CA125 according to the ROC curve were 79.6 and 82.5%, respectively. Also, in work by Tang et al (36), CA153 has been used in the diagnosis of BC with a sensitivity of 63% and a specificity of 82%.

Notably, tumor markers are also helpful to assess a patient with cancer's risk of distant metastasis. Yuan et al (37) observed that CA125 can increase A2780 and OVCAR-3 cell migration, indicating that CA125 may play an important part in tumor metastasis. Moreover, Zhou et al (38) revealed CA125 to be an independent risk factor of bone metastases in patients with lung cancer. Cao et al (31) revealed that CA153 is useful to predict liver metastasis in patients with BC.

OM is often associated with poor prognosis and low quality of life (39). The incidence of OM in BC has varied among different studies, with rates between 5-30% (40,41). The choroid is the most common site of OM owing to its rich blood supply, followed by the orbit, iris, ciliary body, optic nerve, conjunctiva and eyelid (42). When tumor cells grow in these locations, the substances they produce and release enter the blood and can be tested (43). Thus, tumor markers can well reflect the stage of an OM tumor. However, the diagnostic value of tumor markers in OM of patients with BC remains unclear.

The present study analyzed the differences in basic clinical features and common tumor markers between the OM group and NOM group. Among the basic features, ALNM demonstrated significant differences between the two groups. There were also statistically significant differences in CA153 levels in all subgroups and in the whole group, indicating its diagnostic value as a risk factor for OM in patients with BC.

The present study was the first to evaluate the diagnostic value of CA153 in patients with BC with OM. Compared with patients with NOM, patients with OM had higher CA153 levels. The cutoff value was 43.3 µ/ml, suggesting that patients with BC with CA153 levels higher than this value were at risk of OM. Moreover, the sensitivity and specificity for diagnosing OM in patients with BC were 0.96 and 0.96, respectively. Given the high AUC value (0.977), CA153 represents a relatively high predictive accuracy. As an important specific marker of BC, it is widely used in diagnosis of BC and in assessing prognosis and metastasis (44). In a meta-analysis performed by Tang et al (36), the sensitivity and specificity of CA153 in breast secretions for predicting BC were 0.63 and 0.82, respectively. Another meta-analysis conducted by Li et al (45), demonstrated that elevated CA153 is associated with shorter disease-free survival times in patients with BC. In a retrospective study performed by Chen et al (28), CA153 was revealed to be an independent risk factor for BC bone metastases, with sensitivity and specificity of 0.77 and 0.87, respectively.

Although CA153 is an independent risk factor for both bone metastases and OM, there are differences between the two conditions. First, in the present study, bone metastases were more common, whereas OM was relatively rare. Second, OM was more likely to occur at an advanced stage, indicating the progression of the disease, whereas bone metastases could be found in early BC. Third, when bone metastases occurred, elevated CA153 and ALP levels were detected, whereas OM was not associated with high levels of ALP. Regarding the diagnostic value of CA153, high levels of CA153 were detected in both metastases, but with some differences. On the one hand, the cutoff values were different. For diagnosing bone metastases, the cutoff value was 25.42 µ/ml, whereas that for OM was 43.3 µ/ml. On the other hand, the sensitivity and specificity for OM were both >95%. Given these differences and clinical symptoms, it is not difficult to distinguish bone metastases from OM.

However, the present study had some limitations. First, as OM is rare, the sample size was relatively small. Second, the majority of participants were from the same province; more studies of patients from different places are needed. Third, although the present study indicated an association between CA153 and OM, it could not identify their causal relationship. Hence, tests from more institutions are necessary to validate the conclusions of the present study. It would also be appropriate to explore the diagnostic value of CA153 in other metastases. Furthermore, associated molecular experiments could be carried out to explore the specific correlations.

The present study clarified CA153 as an independent risk factor for OM in patients with BC. Patients with BC with CA153 >43.3 µ/ml were more likely to have OM. Although CA153 levels had high predictive value for OM according to the present study, CA153 alone was insufficient to diagnose OM in patients with BC. Combining relevant clinical parameters with clinical symptoms would be an improved strategy. However, the present study indicated that physicians should be vigilant when CA153 levels are over the cutoff value. Treatment should be performed in time to avoid severe metastases. These results will help physicians to improve prediction of OM in patients with BC and provide some insight into the specific mechanisms of tumor markers in cancer metastases.

Acknowledgements

Not applicable.

Data availability and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

YS designed the study. QG, QH and JL analyzed and interpreted the patient data. YS and QG confirm the authenticity of all the raw data. QG, QH, JL, QYL and YS made major contributions writing the manuscript. YM, BL, and RL performed the statistical analyses. WS, QL, QY, and QYL collected the clinical data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of the First Affiliated Hospital of Nanchang University (approval no. CDYFY-2015-112). All patients provided written consent to participate.

Consent for publication

Not applicable.

Conflict of interest

The authors declare that they have no competing interests.

Figure 1 Distributions of patients with BC and conditions of distant organs metastases. (A) Distributions of patients with BC were counted. (B) Other distant metastases of patients with BC were counted. OM, ocular metastases; NOM, non-ocular metastases.

Figure 2 Diagnostic of ocular metastases based on CA153 value. AUC was 0.977 (P<0.001; 95% confidence interval, 0.958-0.995). The cutoff value was 43.3 µ/ml, with a sensitivity of 96.15% and a specificity of 96.02%. AUC, areas under the curve.

Table I Clinical features of patients with breast cancer.

Characteristic	OM	NOM	Whole	P-value	
Age, years±SDa	45.85±7.76	48.31±10.58	48.21±10.48	0.241	
Sex, nb	 	 	 	 	
     Women	26	601	627	1.000	
     Men	0	2	2	 	
Menopausal status, nc	 	 	 	0.248	
     Premenopausal	19	373	392	 	
     Postmenopausal	7	230	237	 	
Histopathology, nc	 	 	 	0.656	
     Invasive ductal carcinoma	20	440	460	 	
     Other types	6	163	169	 	
Axillary lymph node metastases, nc	 	 	 	<0.001	
     0	4	259	263	 	
     1-4	7	210	217	 	
     >4	15	134	149	 	
aUnpaired Student's t-test was used;

bFisher's exact test;

cχ2 test was used. OM, ocular metastases; NOM, non-ocular metastases.

Table II Subgroup analysis.

A, Premenopausal	
Clinical features	OM (n=19)	NOM (n=373)	P-value	
CEA (ng/ml)	39.59±107.83	2.93±9.99	<0.001	
CA125 (µ/ml)	57.23±103.74	22.86±67.94	<0.001	
CA153 (µ/ml)	158.59±129.37	17.16±26.55	<0.001	
CA199 (µ/ml)	30.89±50.44	13.28±13.76	0.375	
ALP (µ/l)	134.32±101.45	59.60±24.64	<0.001	
Calcium (mmol/l)	2.30±0.42	2.32±0.55	0.688	
B, Postmenopausal	
Clinical features	OM (n=7)	NOM (n=230)	P-value	
CEA (ng/ml)	43.56±72.41	39.45±531.00	0.009	
CA125 (µ/ml)	138.19±203.30	24.63±174.47	0.002	
CA153 (µ/ml)	147.14±72.26	19.55±32.91	<0.001	
CA199 (µ/ml)	8.37±4.55	27.50±216.90	0.350	
ALP (µ/l)	107.29±59.49	82.15±42.56	0.391	
Calcium (mmol/l)	2.12±0.60	2.32±0.15	0.622	
C, NALNM	
Clinical features	OM (n=4)	NOM (n=259)	P-value	
CEA (ng/ml)	53.01±101.07	2.39±4.27	0.079	
CA125 (µ/ml)	118.43±209.20	14.84±31.73	0.213	
CA153 (µ/ml)	217.99±219.97	13.13±9.72	<0.001	
CA199 (µ/ml)	11.62±6.95	12.90±11.85	0.920	
ALP (µ/l)	97.50±43.61	63.67±22.47	0.053	
Calcium (mmol/l)	2.65±0.16	2.31±0.13	<0.001	
D, ALNM	
Clinical features	OM (n=22)	NOM (n=344)	P-value	
CEA (ng/ml)	38.41±99.88	27.75±434.30	<0.001	
CA125 (µ/ml)	71.87±126.60	30.08±156.44	<0.001	
CA153 (µ/ml)	144.15±89.88	21.79±37.24	<0.001	
CA199 (µ/ml)	27.22±47.59	23.08±177.62	0.646	
ALP (µ/l)	132.41±97.68	71.61±40.89	<0.001	
Calcium (mmol/l)	2.18±0.47	2.33±0.57	0.235	
E, Bone metastases	
Clinical features	OM (n=25)	NOM (n=62)	P-value	
CEA (ng/ml)	42.14±99.88	141.30±1021.78	0.095	
CA125 (µ/ml)	81.67±140.05	105.98±365.58	0.019	
CA153 (µ/ml)	156.81±117.64	54.64±77.02	<0.001	
CA199 (µ/ml)	25.33±44.89	72.86±416.87	0.704	
ALP (µ/l)	130.00±92.31	102.05±77.10	0.222	
Calcium (mmol/l)	2.26±0.48	2.49±1.30	0.980	
F, Liver metastases	
Clinical features	OM (n=14)	NOM (n=33)	P-value	
CEA (ng/ml)	36.01±56.65	252.70±1400.68	0.009	
CA125 (µ/ml)	53.37±109.41	122.59±462.49	0.061	
CA153 (µ/ml)	140.13±127.64	36.24±53.15	<0.001	
CA199 (µ/ml)	31.53±55.19	117.97±570.94	0.735	
ALP (µ/l)	140.36±101.37	93.33±81.60	0.036	
Calcium (mmol/l)	2.32±0.42	2.30±0.25	0.761	
G, Lung metastases	
Clinical features	OM (n=14)	NOM (n=39)	P-value	
CEA (ng/ml)	53.26±131.52	8.04±29.49	0.047	
CA125 (µ/ml)	78.84±148.35	35.70±90.15	0.023	
CA153 (µ/ml)	131.96±125.65	20.37±21.18	<0.001	
CA199 (µ/ml)	37.96±57.54	14.28±17.47	0.175	
ALP (µ/l)	90.50±42.53	70.69±20.57	0.102	
Calcium (mmol/l)	2.45±0.26	2.31±0.15	0.068	
H, Brain metastases	
Clinical features	OM (n=12)	NOM (n=12)	P-value	
CEA (ng/ml)	20.99±31.48	6.06±8.68	0.160	
CA125 (µ/ml)	77.45±131.97	16.19±12.78	0.012	
CA153 (µ/ml)	185.05±151.17	28.40±21.97	<0.001	
CA199 (µ/ml)	44.28±60.21	10.18±7.11	0.052	
ALP (µ/l)	137.25±105.89	64.42±22.92	0.045	
Calcium (mmol/l)	2.41±0.29	2.24±0.12	0.155	
I, Whole	
Clinical features	OM (n=26)	NOM (n=603)	P-value	
CEA (ng/ml)	40.66±98.15	16.86±328.08	<0.001	
CA125 (µ/ml)	79.03±137.87	23.53±120.14	<0.001	
CA153 (µ/ml)	155.51±115.46	18.07±29.14	<0.001	
CA199 (µ/ml)	24.82±44.05	18.71±134.39	0.792	
ALP (µ/l)	127.04±91.70	68.20±34.42	<0.001	
Calcium (mmol/l)	2.25±0.47	2.32±0.44	0.958	
Mann-Whitney U test was used. OM, ocular metastases; NOM, non-ocular metastases; ALNM, axillary lymph node metastases; NALNM, non-axillary lymph node metastases; CA, Cancer antigen.

Table III Summary of P-values.

Clinical features	PRE	POST	NALNM	ALNM	BM	LIM	LUM	BRM	Whole	
CEA	<0.001	0.009	0.079	<0.001	0.095	0.009	0.047	0.160	<0.001	
CA125	<0.001	0.002	0.213	<0.001	0.019	0.061	0.023	0.012	<0.001	
CA153	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	
CA199	0.375	0.350	0.920	0.646	0.704	0.735	0.175	0.052	0.792	
ALP	<0.001	0.391	0.053	0.000	0.222	0.036	0.102	0.045	<0.001	
Calcium	0.688	0.622	<0.001	0.235	0.980	0.761	0.068	0.155	0.958	
These were the P-values of all subgroup analyses. PRE, premenopausal; POST, postmenopausal; NALNM, non-axillary lymph node metastases; ALNM, axillary lymph node metastases; BM, bone metastases; LIM, liver metastases; LUM, lung metastases; BRM, brain metastases; CEA, carcinoembryonic antigen; CA, cancer antigen; ALP, alkaline phosphatase.

Table IV Binary logistic regression analysis.

Factors	B	Exp(B)	Exp(B) 95% CI	P-value	
CEA	-0.020	0.998	0.992-1.003	0.458	
CA125	0.001	1.001	0.998-1.004	0.464	
CA153	0.028	1.029	1.018-1.039	<0.001	
CA199	0.002	1.002	0.989-1.015	0.759	
ALP	0.001	1.001	0.991-1.010	0.892	
Calcium	-0.064	0.938	0.266-3.311	0.921	
Enter method was used in the binary logistic regression analysis. CI, confidence interval; CEA, carcinoembryonic antigen; CA, cancer antigen; ALP, alkaline phosphatase.

Table V Receiver operating characteristic curve analysis.

Variable	Cutoff value	Sensitivity (%)	Specificity (%)	AUC	95% CI	P-value	
CA153	43.3	96.15	96.02	0.977	0.958-0.995	<0.001	
Sensitivity and specificity were obtained at the point of cutoff value. AUC, area under the curve; CI, confidence interval.

Table VI Literature summary of risk factors for common distant metastases in patients with BC.

Author (Refs.)	Year	Distant metastasis	Risk factors	
Slimane et al (30)	2004	Brain	Negative hormone receptor status	
Cao et al (31)	2012	Liver	Lactate dehydrogenase + γ- glutamyltransferase + CA153	
Chen et al (28)	2017	Bone	Axillary lymph node metastases + CA125 + CA153 + alkaline phosphatase + hemoglobin	
Hu et al (32)	2017	Lung	CD44v	
CA153, cancer antigen 153; CA125, cancer antigen 125.
==== Refs
References

1 Bray F Ferlay J Soerjomataram I Siegel RL Torre LA Jemal A Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394 424 2018 10.3322/caac.21492 30207593
2 Minn AJ Gupta GP Siegel PM Bos PD Shu W Giri DD Viale A Olshen AB Gerald WL Massagué J Genes that mediate breast cancer metastasis to lung Nature 436 518 524 2005 10.1038/nature03799 16049480
3 Bacalbasa N Balescu I Ilie V Florea R Sorop A Brasoveanu V Brezean I Vilcu M Dima S Popescu I The impact on the long-term outcomes of hormonal status after hepatic resection for breast cancer liver metastases In Vivo 32 1247 1253 2018 10.21873/invivo.11372 30150452
4 Oruç Z Kaplan MA Arslan Ç An update on the currently available and future chemotherapy for treating bone metastases in breast cancer patients Expert Opin Pharmacother 19 1305 1316 2018 10.1080/14656566.2018.1504922 30129373
5 Bos PD Zhang XH Nadal C Shu W Gomis RR Nguyen DX Minn AJ van de Vijver MJ Gerald WL Foekens JA Massagué J Genes that mediate breast cancer metastasis to the brain Nature 459 1005 1009 2009 10.1038/nature08021 19421193
6 Liang RB Yu K Wu JL Liu JX Lin Q Li B Zhang YQ Ge QM Li QY Shu HY Shao Y Risk factors and their diagnostic values for ocular metastases in invasive ductal carcinoma Cancer Med 10 824 832 2021 10.1002/cam4.3656 33336932
7 Georgalas I Paraskevopoulos T Koutsandrea C Kardara E Malamos P Ladas D Papaconstantinou D Ophthalmic metastasis of breast cancer and ocular side effects from breast cancer treatment and management: Mini review Biomed Res Int 2015 574086 2015 10.1155/2015/574086 26078956
8 Reddy S Kurli M Tena LB Finger PT PET/CT imaging: Detection of choroidal melanoma Br J Ophthalmol 89 1265 1269 2005 10.1136/bjo.2005.066399 16170113
9 Razek AA Elkhamary S MRI of retinoblastoma Br J Radiol 84 775 784 2011 10.1259/bjr/32022497 21849363
10 Shao YH Tsai K Kim S Wu YJ Demissie K Exposure to tomographic scans and cancer risks JNCI Cancer Spectr 4 pkz072 2019 10.1093/jncics/pkz072 32337490
11 Martin TA Ye L Sanders AJ Lane J Jiang WG Cancer Invasion and Metastasis: Molecular and Cellular Perspective. In: Madame Curie Bioscience Database [Internet]. Landes Bioscience, Austin, TX, 2000-2013.
12 Wagner PD Srivastava S New paradigms in translational science research in cancer biomarkers Transl Res 159 343 353 2012 10.1016/j.trsl.2012.01.015 22424436
13 Shimetani N Status quo of tumor markers and important points in medical practice Rinsho Byori 51 1216 1220 2003 (In Japanese) 14743745
14 Kufe DW Mucins in cancer: Function, prognosis and therapy Nat Rev Cancer 9 874 885 2009 10.1038/nrc2761 19935676
15 Duffy MJ Evoy D McDermott EW CA 15-3: Uses and limitation as a biomarker for breast cancer Clin Chim Acta 411 1869 1874 2010 10.1016/j.cca.2010.08.039 20816948
16 Rahn JJ Dabbagh L Pasdar M Hugh JC The importance of MUC1 cellular localization in patients with breast carcinoma: An immunohistologic study of 71 patients and review of the literature Cancer 91 1973 1982 2001 10.1002/1097-0142(20010601)91:11<1973::aid-cncr1222>3.0.co;2-a 11391575
17 Hayes DF Zurawski VR Kufe DW Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer J Clin Oncol 4 1542 1550 1986 10.1200/JCO.1986.4.10.1542 2428949
18 Stieber P Molina R Chan DW Fritsche HA Beyrau R Bonfrer JM Filella X Gornet TG Hoff T Jäger W Evaluation of the analytical and clinical performance of the Elecsys CA 15-3 immunoassay Clin Chem 47 2162 2164 2001 11719486
19 Stieber P Molina R Chan DW Fritsche HA Beyrau R Bonfrer JM Filella X Gornet TG Hoff T Jäger W Clinical evaluation of the Elecsys CA 15-3 test in breast cancer patients Clin Lab 49 15 24 2003 12593471
20 Bon GG von Mensdorff-Pouilly S Kenemans P van Kamp GJ Verstraeten RA Hilgers J Meijer S Vermorken JB Clinical and technical evaluation of ACS BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays Clin Chem 43 585 593 1997 9105258
21 Colomer R Ruibal A Genollá J Rubio D Del Campo JM Bodi R Salvador L Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases Breast Cancer Res Treat 13 123 133 1989 10.1007/BF01806524 2730960
22 Symeonidis A Kouraklis-Symeonidis A Apostolopoulos D Arvanitopoulou E Giannakoulas N Vassilakos P Zoumbos N Increased serum CA-15.3 levels in patients with megaloblastic anemia due to vitamin B12 deficiency Oncology 67 359 367 2004 10.1159/000082919 15713991
23 Molina R Auge JM Farrus B Zanón G Pahisa J Muñoz M Torne A Filella X Escudero JM Fernandez P Velasco M Prospective evaluation of carcinoembryonic antigen (CEA) and carbohydrate antigen 15.3 (CA 15.3) in patients with primary locoregional breast cancer Clin Chem 56 1148 1157 2010 10.1373/clinchem.2009.135566 20472825
24 Duffy MJ Duggan C Keane R Hill AD McDermott E Crown J O'Higgins N High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: Study of 600 patients with histologically confirmed breast cancer Clin Chem 50 559 563 2004 10.1373/clinchem.2003.025288 14726467
25 Peng S Huang P Yu H Wen Y Luo Y Wang X Zhou J Qin S Li T Chen Y Prognostic value of carcinoembryonic antigen level in patients with colorectal cancer liver metastasis treated with percutaneous microwave ablation under ultrasound guidance Medicine (Baltimore) 97 e0044 2018 10.1097/MD.0000000000010044 29517661
26 Zhao T Hu W CA125 and HE4: Measurement tools for ovarian cancer Gynecol Obstet Invest 81 430 435 2016 10.1159/000442288 27160726
27 Zheng BH Yang LX Sun QM Fan HK Duan M Shi JY Wang XY Zhou J Fan J Ma ZY Gao Q A new preoperative prognostic system combining CRP and CA199 for patients with intrahepatic cholangiocarcinoma Clin Transl Gastroenterol 8 e118 2017 10.1038/ctg.2017.45 28981082
28 Chen WZ Shen JF Zhou Y Chen XY Liu JM Liu ZL Clinical characteristics and risk factors for developing bone metastases in patients with breast cancer Sci Rep 7 11325 2017 10.1038/s41598-017-11700-4 28900285
29 Kashyap D Pal D Sharma R Garg VK Goel N Koundal D Zaguia A Koundal S Belay A Global increase in breast cancer incidence: Risk factors and preventive measures Biomed Res Int 2022 9605439 2022 10.1155/2022/9605439 35480139
30 Slimane K Andre F Delaloge S Dunant A Perez A Grenier J Massard C Spielmann M Risk factors for brain relapse in patients with metastatic breast cancer Ann Oncol 15 1640 1644 2004 10.1093/annonc/mdh432 15520065
31 Cao R Wang LP Serological diagnosis of liver metastasis in patients with breast cancer Cancer Biol Med 9 57 62 2012 10.3969/j.issn.2095-3941.2012.01.011 23691457
32 Hu J Li G Zhang P Zhuang X Hu G A CD44v subpopulation of breast cancer stem-like cells with enhanced lung metastasis capacity Cell Death Dis 8 e2679 2017 10.1038/cddis.2017.72 28300837
33 Brand RE Nolen BM Zeh HJ Allen PJ Eloubeidi MA Goldberg M Elton E Arnoletti JP Christein JD Vickers SM Serum biomarker panels for the detection of pancreatic cancer Clin Cancer Res 17 805 816 2011 10.1158/1078-0432.CCR-10-0248 21325298
34 Stojkovic Lalosevic M Stankovic S Stojkovic M Markovic V Dimitrijevic I Lalosevic J Petrovic J Brankovic M Pavlovic Markovic A Krivokapic Z Can preoperative CEA and CA19-9 serum concentrations suggest metastatic disease in colorectal cancer patients? Hell J Nucl Med 20 41 45 2017 10.1967/s002449910505 28315907
35 Dayyani F Uhlig S Colson B Simon K Rolny V Morgenstern D Schlumbrecht M Diagnostic performance of risk of ovarian malignancy algorithm against CA125 and HE4 in connection with ovarian cancer: A meta-analysis Int J Gynecol Cancer 26 1586 1593 2016 10.1097/IGC.0000000000000804 27540691
36 Tang S Wei L Sun Y Zhou F Zhu S Yang R Huang Y Zhang H Xu H Yang J CA153 in breast secretions as a potential molecular marker for diagnosing breast cancer: A meta analysis PLoS One 11 e0163030 2016 10.1371/journal.pone.0163030 27636552
37 Yuan Q Song J Yang W Wang H Huo Q Yang J Yu X Liu Y Xu C Bao H The effect of CA125 on metastasis of ovarian cancer: Old marker new function Oncotarget 8 50015 50022 2017 10.18632/oncotarget.18388 28637006
38 Zhou Y Yu QF Peng AF Tong WL Liu JM Liu ZL The risk factors of bone metastases in patients with lung cancer Sci Rep 7 8970 2017 10.1038/s41598-017-09650-y 28827719
39 Lin Q Chen XY Liu WF Zhu PW Shi WQ Li B Yuan Q Min YL Liu JM Shao Y Diagnostic value of CA-153 and CYFRA 21-1 in predicting intraocular metastasis in patients with metastatic lung cancer Cancer Med 9 1279 1286 2020 10.1002/cam4.2354 31218849
40 Kreusel KM Wiegel T Stange M Bornfeld N Foerster MH Intraocular metastases of metastatic breast carcinoma in the woman. Incidence, risk factors and therapy Ophthalmologe 97 342 326 2000 10.1007/s003470050534 (In German) 10892278
41 Nelson CC Hertzberg BS Klintworth GK A histopathologic study of 716 unselected eyes in patients with cancer at the time of death Am J Ophthalmol 95 788 793 1983 10.1016/0002-9394(83)90066-1 6859188
42 Demirci H Shields CL Chao AN Shields JA Uveal metastasis from breast cancer in 264 patients Am J Ophthalmol 136 264 271 2003 10.1016/s0002-9394(03)00192-2 12888048
43 Tarro G Perna A Esposito C Early diagnosis of lung cancer by detection of tumor liberated protein J Cell Physiol 203 1 5 2005 10.1002/jcp.20195 15389637
44 Lu F Pan S Qi Y Li X Wang J The clinical application value of RDW, CA153, and MPV in breast cancer Clin Lab 67 2021 10.7754/Clin.Lab.2020.200507 33616344
45 Li X Dai D Chen B Tang H Xie X Wei W Clinicopathological and prognostic significance of cancer antigen 15-3 and carcinoembryonic antigen in breast cancer: A Meta-analysis including 12,993 patients Dis Markers 2018 9863092 2018 10.1155/2018/9863092 29854028
